{"id":4164,"date":"2026-11-09T09:00:00","date_gmt":"2026-11-09T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4164"},"modified":"2026-11-09T21:32:37","modified_gmt":"2026-11-10T01:32:37","slug":"rese-cel-autoimmune-follow-up-reaches-one-year","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4164","title":{"rendered":"Rese Cel Autoimmune Follow Up Reaches One Year"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Cabaletta_Bio_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4167\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Cabaletta_Bio_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Cabaletta_Bio_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Cabaletta_Bio_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Cabaletta_Bio_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Cabaletta Bio<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Updated clinical follow-up (SEC 8-K)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Autologous CD19 CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Resecabtagene autoleucel (rese-cel)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD19<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Dermatomyositis; lupus nephritis; systemic sclerosis<\/p>\n<h4>Summary<\/h4>\n<p>Cabaletta disclosed updated single-arm rese-cel outcomes across autoimmune cohorts. Six of six dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses at one year. The signal is clinically meaningful but small-cohort selection, optional biopsies and lack of control limit causal and comparative conclusions.<\/p>\n<p>A November 9 SEC 8-K and attached release report a September 4 cutoff. Six of six dermatomyositis patients met the stated one-year TIS threshold without immunomodulators; five of six did so at week 16. Five of five lupus nephritis patients who underwent optional repeat biopsy met DORIS remission and histologic response or remission. Five of seven systemic sclerosis patients achieved rCRISS-50 at one year, while five patients with interstitial lung disease had a mean nine-percent improvement in percent-predicted FVC. Across 71 treated patients, four had grade 2 CRS, three had ICANS of any grade, and none had reported IEC-HS. The dermatomyositis oral presentation occurred November 8; the November 9 disclosure adds consolidated follow-up and other cohorts.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>Rese-cel is an autologous CD19 CAR T strategy intended to reset pathogenic B-cell compartments after preconditioning. One-year immunomodulator-free status plus disease-specific response is more informative than early cell-depletion biomarkers. The biopsied nephritis subset adds tissue evidence but optional rebiopsy can select favorable patients; persistent proteinuria can reflect chronic damage or residual activity, requiring adjudicated longitudinal pathology. Dermatomyositis TIS, systemic sclerosis rCRISS and pulmonary FVC are different endpoints and must not be pooled as one efficacy rate. Small samples make estimates unstable; concurrent steroid changes, baseline severity, rescue treatment, missing data and cohort entry rules should be examined in the full dataset. Safety characterization needs exposure-adjusted infection, cytopenia, hypogammaglobulinemia and late-event follow-up. A planned registrational cohort and proposed BLA timing are future catalysts, not approvals.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Cabaletta Bio develops resecabtagene autoleucel, an autologous anti-CD19 CAR T cell product, for B-cell-driven autoimmune diseases. Dermatomyositis causes inflammatory muscle and skin disease; lupus nephritis injures the kidney; systemic sclerosis causes fibrosis and vascular disease.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li><strong>Interpretation A:<\/strong> durable immune reset is producing treatment-free clinical benefit; one-year responses across multiple measures support this. Contradiction: no randomized comparator and very small disease cohorts.<\/li>\n<li><strong>Interpretation B:<\/strong> selection and regression to the mean inflate apparent durability; optional renal biopsies and uncontrolled treatment changes support caution. Contradiction: repeated clinical and histologic changes are harder to dismiss as measurement noise alone.<\/li>\n<li><strong>Upgrade:<\/strong> with prespecified registrational outcomes, complete denominators and long-term organ function; <strong>Downgrade:<\/strong> with relapse after immunomodulator withdrawal or late toxicity; <strong>Falsification:<\/strong> broad durability claims if larger cohorts fail prespecified disease endpoints.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Rese-cel has a credible durability signal in refractory autoimmunity, especially dermatomyositis, but the apparent cross-disease breadth and benefit-risk profile need larger, complete datasets. The November 9 filing merits a report as new follow-up, not as an approval or pivotal result.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: mixed. Confidence in Facts: high for filed data. Confidence in Interpretation: moderate to low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cabaletta disclosed updated single-arm rese-cel outcomes across autoimmune cohorts. Six of six dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses at one year. The signal is clinically meaningful but small-cohort selection, optional biopsies and lack&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[261,453,1414],"class_list":["post-4164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-cabaletta-bio","tag-dermatomyositis","tag-rese-cel"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4164"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4164\/revisions"}],"predecessor-version":[{"id":4174,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4164\/revisions\/4174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4167"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}